Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance [1][3] - The company will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [1] - Praxis utilizes genetic insights to develop therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] Company Overview - Praxis Precision Medicines specializes in translating genetic insights from genetic epilepsies into therapies for CNS disorders [3] - The company has established a diversified portfolio that includes multiple programs across movement disorders and epilepsy, featuring four clinical-stage product candidates [3] - The company’s approach leverages an understanding of shared biological targets and circuits in the brain [3] Event Information - A live webcast of the corporate overview will be available, with a replay accessible for 30 days on the company's website [2]